帕金森病认知障碍  

Parkinson′s disease with cognitive impairment

作　　者：马春潮[1] 朱晓冬[2] MA Chun-chao;ZHU Xiao-dong(Department of Neurology,Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津市第一中心医院神经内科,天津300192 [2]天津医科大学总医院神经内科,天津300052

出　　处：《中国实用内科杂志》2019年第9期769-774,共6页Chinese Journal of Practical Internal Medicine

摘　　要：帕金森病(PD)是一种进行性神经退行性疾病,以运动迟缓、静止震颤、肌强直等运动症状为特征。然而证据表明帕金森病也存在包括认知障碍在内的一些非运动症状。从疾病的早期阶段开始,就可出现轻度认知障碍,其特征是包括执行功能、注意力和视觉空间技能、语言和记忆在内的多领域认知障碍,在疾病的晚期阶段,可发展为帕金森病痴呆,并存在相当大的异质性。本综述重点关注帕金森病认知障碍的临床特点、生物标志物,以及药物、非药物治疗的研究进展,以期为临床实践提供帮助。Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by motor symptoms such as rigidity, rest tremor, and bradykinesia. However, evidence demonstrated that PD encompasses several non-motor disturbances as well, such as cognitive impairment. Mild cognitive impairment can be present since early stages of the disease, and characterized by impairments in several cognitive domains including executive functions, attention, and visuospatial skills, language, and memory;In advanced stages of the disease, cognitive defects can develop into dementia and there is a considerable heterogeneity in the cognitive impairments. In this review, we focus on the clinical characteristics, biomarkers, and drug and non-drug treatments of cognitive impairment in Parkinson's disease;hoping to provide help for clinical practice.

关 键 词：帕金森病 帕金森病轻度认知功能障碍 帕金森病痴呆 生物标志物 胆碱酯酶抑制剂 

分 类 号：R742.5[医药卫生—神经病学与精神病学]